NCT06580574View on ClinicalTrials.gov

Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon Cancers

PHASE2RecruitingINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

August 13, 2024

Primary Completion Date

June 1, 2029

Study Completion Date

June 1, 2029

Conditions
Gastric CancerColon CancerMSI-HDMMR Cancer
Interventions
DRUG

PD1/PDL1 antibody monotherapy, up to 24 weeks

non-specific, according to Drug Instructions

COMBINATION_PRODUCT

Intensive immunotherapy plus anti-VEGF treatment, up to 24 weeks

Sintilimab 200mg, ivgtt, q21d; IBI310 1mg/kg, ivgtt, q42d; Lenvatinib 8mg (starting from 4mg), po, qd

PROCEDURE

Radical surgery

Radical surgery will be recommended per local treatment standards.

Trial Locations (1)

100142

RECRUITING

Beijing Cancer Hospital, Beijing

All Listed Sponsors
lead

Peking University

OTHER